Matysiak-Klose Dorothea, Mankertz Annette, Holzmann Heidemarie
Department of Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Berlin, Germany; Department of Infectious Diseases, Measles, Mumps, Rubella, and Viruses Affecting Immunocompormised Patients, Robert Koch Institute, Berlin, Germany; Scientific Commitees, National Verification Committee for Measles and Rubella elimination in Germany, Berlin, Germany.
Dtsch Arztebl Int. 2024 Dec 27;121(26):875-881. doi: 10.3238/arztebl.m2024.0211.
Measles is a highly contagious viral disease (contagion index near 100%) with a complication rate of up to 30%. The worldwide incidence for 2022 was calculated as 29 cases per million people. Measles can be eliminated if 95% of the population is either vaccinated or immune and measures are taken to limit its spread as soon as an initial suspected case is encountered. However, the worldwide immunization rate has fallen since 2020 (from 86% in 2019 to 81% in 2021).
To assess the epidemiological situation and describe the state of scientific knowledge regarding laboratory tests for measles, we analyzed recent epidemiological data from the Robert-Koch Institute (RKI) and reviewed pertinent publications retrieved by a selective literature search.
Repeated importations of measles virus have led to a new rise in case numbers in Germany since last year. 79 cases of measles were reported to the RKI in 2023, and 475 in the first eight months of 2024. The latter figure corresponds to the pre-pandemic level. There are still immunization gaps in the population: for instance, by the age of 24 months, 93.7% of children have received their first immunization, and only 80.5% have received the second. Every suspected case must be confirmed by laboratory testing so that targeted measures can be initiated. Serology is no longer considered sufficiently reliable; a reliable diagnosis now requires a poly merase chain reaction (PCR) test. The specimen can be a throat swab or a urine sample. PCR also enables the differentiation of measles virus variants and the tracing of transmission chains.
Reliable laboratory testing makes it possible to detect measles cases rapidly, initiate measures to slow the spread of the disease, trace infection chains, and assess the risk exposure for measles in Germany.
麻疹是一种高度传染性的病毒性疾病(传染指数接近100%),并发症发生率高达30%。2022年全球发病率经计算为每百万人29例。如果95%的人口接种疫苗或具有免疫力,并在遇到首例疑似病例时立即采取措施限制其传播,麻疹是可以被消除的。然而,自2020年以来,全球免疫接种率有所下降(从2019年的86%降至2021年的81%)。
为评估麻疹的流行病学情况并描述有关麻疹实验室检测的科学知识状况,我们分析了罗伯特·科赫研究所(RKI)的最新流行病学数据,并回顾了通过选择性文献检索获得的相关出版物。
自去年以来,麻疹病毒的多次输入导致德国病例数再次上升。2023年向RKI报告了79例麻疹病例,2024年的前八个月报告了475例。后一数字与疫情前水平相当。人群中仍存在免疫差距:例如,到24个月大时,93.7%的儿童接受了首次免疫接种,只有80.5%的儿童接受了第二次免疫接种。每个疑似病例都必须通过实验室检测进行确诊,以便能够启动针对性措施。血清学不再被认为足够可靠;现在可靠的诊断需要进行聚合酶链反应(PCR)检测。样本可以是咽拭子或尿液样本。PCR还能够区分麻疹病毒变种并追踪传播链。
可靠的实验室检测能够快速检测出麻疹病例,启动减缓疾病传播的措施,追踪感染链,并评估德国麻疹的风险暴露情况。